BRPI0111220B1 - conjugados de fármacos com etilenodicisteína (ec) - Google Patents

conjugados de fármacos com etilenodicisteína (ec)

Info

Publication number
BRPI0111220B1
BRPI0111220B1 BRPI0111220A BR0111220A BRPI0111220B1 BR PI0111220 B1 BRPI0111220 B1 BR PI0111220B1 BR PI0111220 A BRPI0111220 A BR PI0111220A BR 0111220 A BR0111220 A BR 0111220A BR PI0111220 B1 BRPI0111220 B1 BR PI0111220B1
Authority
BR
Brazil
Prior art keywords
drug conjugates
ethylenedicistein
chelated
specific
diseases
Prior art date
Application number
BRPI0111220A
Other languages
English (en)
Other versions
BR0111220A (pt
BRPI0111220B8 (pt
Inventor
Chun-Wei Liu
David J Yang
Dong-Fang Yu
E Edmund Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/599,152 external-priority patent/US7067111B1/en
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR0111220A publication Critical patent/BR0111220A/pt
Publication of BRPI0111220B1 publication Critical patent/BRPI0111220B1/pt
Publication of BRPI0111220B8 publication Critical patent/BRPI0111220B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"conjugados de fármacos de etilenodicisteína (ec)". a invenção fornece, num sentido geral, uma nova estratégia de rotulação com emprego de 99tc quelado com etilenodicisteína (ec). ec é conjugada com uma variedade de ligantes e quelada ao ^ 99m^tc para uso em um agente de geração de imagem para doenças específicas de tecido. os conjugados do fármaco da invenção podem também ser usados como uma ferramenta de prognóstico ou como uma ferramenta para entregar compostos terapêuticos a sítios específicos num corpo de mamífero. estojos para uso na geração de imagem de doenças específicas de tecido são também providos.
BRPI0111220A 2000-06-02 2001-06-01 conjugados de fármacos com etilenodicisteína (ec) BRPI0111220B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58758300A 2000-06-02 2000-06-02
US09/599,152 US7067111B1 (en) 1999-10-25 2000-06-21 Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PCT/US2001/018060 WO2001091807A2 (en) 2000-06-02 2001-06-01 Ethylenedicysteine (ec)-drug conjugates

Publications (3)

Publication Number Publication Date
BR0111220A BR0111220A (pt) 2003-06-24
BRPI0111220B1 true BRPI0111220B1 (pt) 2016-10-11
BRPI0111220B8 BRPI0111220B8 (pt) 2021-07-27

Family

ID=27080078

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111220A BRPI0111220B8 (pt) 2000-06-02 2001-06-01 conjugados de fármacos com etilenodicisteína (ec)

Country Status (15)

Country Link
US (4) US7615208B2 (pt)
EP (2) EP2316494A1 (pt)
JP (3) JP5448284B2 (pt)
KR (1) KR100784120B1 (pt)
CN (1) CN1292798C (pt)
AU (2) AU7521001A (pt)
BR (1) BRPI0111220B8 (pt)
CA (1) CA2410906C (pt)
DK (1) DK1286704T3 (pt)
ES (1) ES2518926T3 (pt)
HU (1) HU230437B1 (pt)
IL (2) IL153218A0 (pt)
NO (1) NO332574B1 (pt)
PL (1) PL212211B1 (pt)
WO (1) WO2001091807A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
IL153218A0 (en) * 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
CA2443314C (en) * 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
CA2480408A1 (en) * 2002-02-26 2003-09-04 Masahiro Murakami A method for encapsulating metal complex in liposomes
US7824661B2 (en) 2002-03-11 2010-11-02 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
AU2003213819C1 (en) 2002-03-11 2010-03-04 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
JP4801348B2 (ja) 2002-05-06 2011-10-26 エンドサイト，インコーポレイテッド ビタミンを標的とした造影剤
KR101086690B1 (ko) 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2005079865A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
WO2005087275A2 (en) * 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
CA2603437A1 (en) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Poly(peptide) as a chelator: methods of manufacture and uses
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
WO2008064040A2 (en) * 2006-11-22 2008-05-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
WO2009120244A1 (en) * 2008-03-24 2009-10-01 The Board Of Regents Of The University Of Texas System Image-guided therapy of myocardial disease: composition, manufacturing and applications
CN101721720B (zh) * 2008-10-29 2011-08-24 阮建评 硝咪唑-氨基酸化合型核素乏氧造影剂及其前体
WO2011044377A2 (en) * 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
US20110280770A1 (en) * 2010-05-12 2011-11-17 Jeffrey Lacy Nanogenerator
PL2721045T3 (pl) * 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
PL2830666T3 (pl) 2012-03-26 2021-03-08 Board Of Regents, The University Of Texas System Skuteczna synteza koniugatów etylenodicysteina-cukier do obrazowania i terapii
US9886546B2 (en) 2012-11-20 2018-02-06 General Electric Company Methods and apparatus to label radiology images
EP3533473A3 (en) * 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
WO2017030893A1 (en) 2015-08-14 2017-02-23 Endocyte, Inc. Method of imaging with a chelating compound
US10905783B2 (en) 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
CN111372940A (zh) * 2017-09-19 2020-07-03 阿尔伯塔大学理事会 生物还原活化的化合物、其前药、放射性药物、组合物及其在包括癌症在内的低氧疾病的多模式治疗控制中的应用
RU2692451C2 (ru) * 2017-10-02 2019-06-24 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ радионуклидной диагностики опухолей головного мозга
DK3704082T3 (da) 2017-12-21 2022-03-21 Univ Free State Multinukleære komplekser og deres fremstilling
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
US20210393786A1 (en) * 2018-07-26 2021-12-23 Purdue Research Foundation Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CN113041366A (zh) * 2021-03-12 2021-06-29 青岛大学附属医院 一种新型肿瘤乏氧正电子显像剂及其制备方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141654A (en) 1977-05-23 1979-02-27 James V. Massey, III Standard for calibrating and/or verifying instrument accuracy
US4279992A (en) 1978-03-13 1981-07-21 Miles Laboratories, Inc. Specific binding assay employing an enzyme-cleavable substrate as label
US4181654A (en) 1978-07-24 1980-01-01 The United States Of America As Represented By The United States Department Of Energy 2,3-Dihydroxybenzoic acid amides of tetraazaalkanes and tetaaza cycloalkanes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5648063A (en) 1981-07-24 1997-07-15 Schering Aktiengesellschaft Sterile composition comprising a chelate complex for magnetic resonance imaging
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5242679A (en) 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
GB8525974D0 (en) 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4789542A (en) 1986-04-29 1988-12-06 The United States Of America As Represented By The United States Department Of Energy Radioiodinated glucose analogues for use as imaging agents
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
IN165717B (pt) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4730968A (en) 1986-09-08 1988-03-15 David Diperstein Self-tapping, self-aligning thread repair insert
US5279811A (en) 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US5164294A (en) 1988-05-17 1992-11-17 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5071965A (en) 1988-07-19 1991-12-10 Mallinckrodt Medical, Inc. Novel tc-99m complexes
US4925650A (en) 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
WO1991016076A1 (en) 1990-04-17 1991-10-31 Mallinckrodt Medical, Inc. Method and kit for preparing technetium-99m complexes
EP0548245A1 (en) * 1990-06-18 1993-06-30 Mallinckrodt Medical, Inc. Metal-radionuclide complex comprising isonitrile ligands
US5385719A (en) 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
JPH07501058A (ja) 1991-11-08 1995-02-02 キュレイターズ　オブ　ザ　ユニヴァーシティー　オブ　ミズーリー 治療または診断用の放射性薬品の像形成剤の設計における潜在的な使用のための新規な多官能リガンド
US5310536A (en) 1992-02-06 1994-05-10 Mallinckrodt Medical, Inc. Ligands for improving metal chelate formation kinetics
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP0646019B9 (en) 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5496533A (en) * 1992-07-31 1996-03-05 Australian Nuclear Science & Technology Organisation Rhenium complexes
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5951964A (en) 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
JPH07126165A (ja) * 1993-10-29 1995-05-16 Masao Oguro 腫瘍治療剤
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
AU2194695A (en) 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5730968A (en) 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
AU3876695A (en) 1994-11-17 1996-06-17 Imperial College Of Science, Technology And Medicine Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US5643883A (en) 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
US5955605A (en) 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
JP3543201B2 (ja) * 1995-10-03 2004-07-14 日本ペイント株式会社 熱硬化性樹脂粒子の製造方法
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
JP3963996B2 (ja) * 1996-03-28 2007-08-22 日本メジフィジックス株式会社 糖代謝機能診断剤
US5986074A (en) 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
IT1284046B1 (it) 1996-06-21 1998-05-08 Bracco Spa Processo per la preparazione di tetraazamacrocicli
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
ES2244006T3 (es) 1996-08-27 2005-12-01 University Of Utah Research Foundation Bioconjugados y administracion de agentes bioactivos.
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2392246T3 (es) 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
EP0885704B1 (en) * 1996-12-18 2003-08-06 Toray Industries, Inc. Carbon fiber prepreg and method of production thereof
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
EP0879606A1 (en) * 1997-04-25 1998-11-25 Paul Scherrer Institut Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
KR20010020443A (ko) 1997-04-30 2001-03-15 캐서린 구 생체내 세포 치사를 이미지화시키는 방법
JP3794517B2 (ja) * 1997-05-08 2006-07-05 日本メジフィジックス株式会社 腫瘍診断剤
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
KR20050009764A (ko) * 1997-11-25 2005-01-25 제넨테크, 인크. 섬유아세포 성장 인자-19
AU2530199A (en) 1998-02-06 1999-08-23 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
JP2002513776A (ja) 1998-05-07 2002-05-14 イムノメディクス， インコーポレイテッド ガリウム−６８キレートを使用した陽電子放射断層撮影法
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
GB9811059D0 (en) 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
IL139641A0 (en) 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
IT1302125B1 (it) 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
DE19905094C1 (de) 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
JP2002540073A (ja) 1999-03-10 2002-11-26 ロータス バイオケミカル コーポレイション 化学化合物の保護および放出のためのタンパク質コンホメーションの使用
US20010041189A1 (en) 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
CA2406852A1 (en) 2000-04-20 2001-11-01 The University Of British Columbia Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy
US20040072168A1 (en) 2000-05-12 2004-04-15 Wolfgang Knecht Novel deoxynucleoside kinase enzyme variants
DE10024874A1 (de) 2000-05-16 2001-11-29 Siemens Ag Polierflüssigkeit und Verfahren zur Strukturierung von Metallen und Metalloxiden
IL153218A0 (en) 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
US6440389B1 (en) 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
FR2811985A1 (fr) 2000-07-19 2002-01-25 Univ Bretagne Occidentale Procede de synthese de la n1, n3-bis(2-aminoethyl)propane- 1,3-diamine, intermediaires de synthese, produits ainsi obtenus et leur application a la synthese de cyclam
WO2002011677A2 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
WO2002032291A2 (en) 2000-10-19 2002-04-25 The General Hospital Corporation Imaging of enzymatic activity
KR20030051828A (ko) 2000-11-16 2003-06-25 파마시아 앤 업존 컴파니 에스트로겐 의존성 질환의 병용 치료법
WO2002043775A2 (en) 2000-11-20 2002-06-06 GODFREY, Cullen, M. Paramagnetic metal ion-based macrocyclic contrast agents
AU2002246827B2 (en) 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
JP2002241307A (ja) 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030152512A1 (en) 2001-11-13 2003-08-14 Milind Rajopadhye Imaging thrombus with glycoprotein llb/llla antagonists
WO2003051403A1 (en) 2001-12-13 2003-06-26 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US7121926B2 (en) 2001-12-21 2006-10-17 Micron Technology, Inc. Methods for planarization of group VIII metal-containing surfaces using a fixed abrasive article
BRPI0511645A (pt) 2004-08-13 2008-01-02 Lg Electronics Inc estabelecimento de conexão de controle de recursos de rádio em sistema de comunicação sem fios

Also Published As

Publication number Publication date
US20140200329A1 (en) 2014-07-17
WO2001091807A2 (en) 2001-12-06
WO2001091807A3 (en) 2002-08-29
EP2316494A1 (en) 2011-05-04
US8236279B2 (en) 2012-08-07
NO20025729D0 (no) 2002-11-28
EP1286704B1 (en) 2014-07-23
HUP0300951A2 (hu) 2003-07-28
PL359337A1 (en) 2004-08-23
JP2012193199A (ja) 2012-10-11
HUP0300951A3 (en) 2005-11-28
US20100055035A1 (en) 2010-03-04
BR0111220A (pt) 2003-06-24
US20070297976A1 (en) 2007-12-27
AU2001275210B2 (en) 2006-09-28
IL153218A (en) 2010-02-17
JP2008208138A (ja) 2008-09-11
DK1286704T3 (da) 2014-09-22
AU7521001A (en) 2001-12-11
CA2410906A1 (en) 2001-12-06
US7615208B2 (en) 2009-11-10
JP2003534388A (ja) 2003-11-18
BRPI0111220B8 (pt) 2021-07-27
IL153218A0 (en) 2003-07-06
US20130165631A1 (en) 2013-06-27
KR100784120B1 (ko) 2007-12-12
HU230437B1 (hu) 2016-06-28
NO332574B1 (no) 2012-11-05
JP5448284B2 (ja) 2014-03-19
JP5781026B2 (ja) 2015-09-16
CN1292798C (zh) 2007-01-03
CN1438899A (zh) 2003-08-27
KR20030031905A (ko) 2003-04-23
HK1056682A1 (zh) 2004-02-27
NO20025729L (no) 2003-01-29
CA2410906C (en) 2012-10-02
ES2518926T3 (es) 2014-11-05
EP1286704A2 (en) 2003-03-05
PL212211B1 (pl) 2012-08-31

Similar Documents

Publication Publication Date Title
BRPI0111220B1 (pt) conjugados de fármacos com etilenodicisteína (ec)
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
BR0010478A (pt) Vacina de célula total contendo antìgeno de staphyloccocus aureus
BR0113524A (pt) Composição antiperspirante e/ou desodorante sólida
BR0206985A (pt) Anticorpos modificados e métodos de uso
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
BR9807055A (pt) Composição farmacêutica, uso de um agente fotoquimioterapêutico precursor da protoporfirina junto com um fotossensibilizador de localização de estroma vascular, produto contendo os mesmos, kit para uso em fotoquimioterapia de distúrbios ou anormalidades das superfìcies externa ou interna do corpo, e, processos de tratamento fotoquimioterapêutico de distúrbios ou anormalidades de superfìcies externa ou interna do corpo, e de diagnóstico in vitro de anormalidades ou distúrbios, mediante ensaios de uma amostra de fluidos corporais ou tecidos de um paciente
BR0015194A (pt) Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
AR049829A1 (es) Procedimiento y composiciones utiles para prevenir y/o tratar las pieles sensibles y/o secas
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
BR0109280A (pt) Artigo absorvente para ser usado por um usuário adjacente à pele e processo para produzir o mesmo
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
BRPI0401758A (pt) Composição farmacêutica analgésica tópica, luva, e, métodos para aplicar uma luva a uma extremidade humana com uma área afetada, para preparar uma luva, e para aperfeiçoar uma função de junta
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
GB9610971D0 (en) A diagnostic test for use in schizophrenia
BRPI0518328A2 (pt) agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica
BR9809785A (pt) Composto de ligação de receptor de calcitonina, reagente, agente de formação de imagem cintigráfica, composição, agente radio-terapêutico, complexo, kit para preparar uma preparação radio-farmacêutica, processos para rotular o reagente, para fabricar o reagente, e, uso do reagente

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2001, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/06/2021